GlyphAllo (allopregnanolone prodrug) vs HS-10353
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline
GlyphAllo (allopregnanolone prodrug) · SPT-300
Developed by Seaport Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07065240 (registry estimate)
No aligned efficacy figure on record for this race.
HS-10353
Developed by Hansoh Pharmaceutical Group
NCT05195203 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Endpoints of the trial:AE,SAE". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Endpoints of the trial:AE,SAE (Baseline to end of follow-up (a maximum of 20 days)): Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Result source: NCT05195203
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | GlyphAllo (allopregnanolone prodrug) | HS-10353 |
|---|---|---|
| MADRS, change (acute) | —Not reported | —Not reported |
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- GlyphAllo (allopregnanolone prodrug)
- —Not reported
- HS-10353
- —Not reported
CGI-S, change (acute)
- GlyphAllo (allopregnanolone prodrug)
- —Not reported
- HS-10353
- —Not reported
MADRS response
- GlyphAllo (allopregnanolone prodrug)
- —Not reported
- HS-10353
- —Not reported
MADRS remission
- GlyphAllo (allopregnanolone prodrug)
- —Not reported
- HS-10353
- —Not reported
Relapse (% of patients)
- GlyphAllo (allopregnanolone prodrug)
- —Not reported
- HS-10353
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
GlyphAllo (allopregnanolone prodrug): no structured comparison results are available for Major Depressive Disorder.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GlyphAllo (allopregnanolone prodrug)'s landscape · HS-10353's landscape